Study to Evaluate the Safety, Efficacy, and Pharmacology of ARINA-1

 

Phase: 2a

Status: Ongoing

Details

RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.

Sponsor: Renovion, Inc.

NCT05495243 - IRB# 2022-058